Related references
Note: Only part of the references are listed.Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada
Lauren J. Lee et al.
LEUKEMIA & LYMPHOMA (2018)
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations
Martin Dreyling et al.
LEUKEMIA & LYMPHOMA (2018)
The Influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
T. Magnes et al.
PHARMACOGENOMICS JOURNAL (2018)
Advances in chronic lymphocytic leukemia pharmacotherapy
Lorena Caixeta Gomes et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
Julie E. Chang et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab
Maeve P. Crowley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma
Emilie Fargier et al.
ANNALS OF HEMATOLOGY (2018)
Current prognostic and predictive factors in follicular lymphoma
Marc Sorigue et al.
ANNALS OF HEMATOLOGY (2018)
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Michael R. Grever et al.
BLOOD (2017)
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Jeff P. Sharman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Laura M. Rogers et al.
CLINICAL CANCER RESEARCH (2017)
Rethinking the INN system for therapeutic antibodies
Jeremy Pottier et al.
MABS (2017)
Follicular Lymphoma: The Management of Elderly Patient
Alessia Castellino et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
Rituximab maintenance improves overall survival of patients with follicular lymphoma Individual patient data meta-analysis
Liat Vidal et al.
EUROPEAN JOURNAL OF CANCER (2017)
TP53 mutation and survival in aggressive B cell lymphoma
Thorsten Zenz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparability study of Rituximab originator and follow-on biopharmaceutical
Othman Montacir et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab
Jerrard M. Hayes et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
MARKET WATCH Strategies for biosimilars in emerging markets 2014
Ajay Gautam
NATURE REVIEWS DRUG DISCOVERY (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
S. Le Gouill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Humanized mouse model supports development, function, and tissue residency of human natural killer cells
Dietmar Herndler-Brandstetter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
Sohita Dhillon
TARGETED ONCOLOGY (2017)
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
Laura Collett et al.
TRIALS (2017)
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives
Annalisa Chiappella et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Current options to manage Waldenstrom's macroglobulinemia
Giulia Benevolo et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Alice Di Rocco et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
Othman Al-Sawaf et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Current perspective on rituximab in rheumatic diseases
Tommaso Schioppo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10
Bertrand Coiffier
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies
Christophe Lallemand et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Modeling Natural Killer Cell Targeted Immunotherapies
Silvia Lopez-Lastra et al.
FRONTIERS IN IMMUNOLOGY (2017)
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Wojciech Jurczak et al.
LANCET HAEMATOLOGY (2017)
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
Won Seog Kim et al.
LANCET HAEMATOLOGY (2017)
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
Stuart W. Hicks et al.
NEOPLASIA (2017)
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
Janakiraman Subramanian et al.
CANCER MANAGEMENT AND RESEARCH (2017)
Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
Xuan Zhou et al.
PLOS ONE (2017)
Biosimilars: Key regulatory considerations and similarity assessment tools
Carol F. Kirchhoff et al.
BIOTECHNOLOGY AND BIOENGINEERING (2017)
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
Michael Pfreundschuh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma
Huabin Yin et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2017)
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)
P. Martin et al.
ANNALS OF ONCOLOGY (2017)
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies et al.
ADVANCES IN THERAPY (2017)
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia
Jonas Paludo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era
L. A. Butler et al.
BLOOD REVIEWS (2017)
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
Dae Hyun Yoo et al.
BIODRUGS (2017)
Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies
Rut Valgardsdottir et al.
BLOOD (2017)
Primary mediastinal large B-cell lymphoma
Maurizio Martelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
Amit Dipak Amin et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Whither Radioimmunotherapy: To Be or Not To Be?
Damian J. Green et al.
CANCER RESEARCH (2017)
Diagnosis and treatment of CD20 negative B cell lymphomas
Tasleem Katchi et al.
BIOMARKER RESEARCH (2017)
Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?
Michael T. Tees et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Arne Kolstad et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Treatment of splenic marginal zone lymphoma
Christina Kalpadakis et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Rituximab: 13 open questions after 20 years of clinical use
Francesca Pavanello et al.
CANCER TREATMENT REVIEWS (2017)
Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis
Man Nie et al.
ANNALS OF HEMATOLOGY (2016)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia
Birgit Burkhardt et al.
ANNALS OF HEMATOLOGY (2016)
Optimizing therapy for nodal marginal zone lymphoma
Catherine Thieblemont et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
Dai Chihara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Gota et al. on their article the pharmacokinetics of Reditux™, a biosimilar of rituximab
Mira Tout et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma
Vikram Gota et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections
Narges Seyfizadeh et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S. Nowakowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag et al.
LANCET (2016)
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
Mark D. Danese et al.
MEDICAL CARE (2016)
Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Ramraj Velmurugan et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells
Makiko Yamashita et al.
SCIENTIFIC REPORTS (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S. Nowakowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Natural killer cell memory in infection, inflammation and cancer
Adelheid Cerwenka et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens
Hsiao-Han Wang et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma
Myron S. Czuczman et al.
ANNALS OF HEMATOLOGY (2015)
Historical overview of hairy cell leukemia
Leslie A. Andritsos et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2015)
Biosimilars advancements: Moving on to the future
Lilian Rumi Tsuruta et al.
BIOTECHNOLOGY PROGRESS (2015)
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL
Aradhana Awasthi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Ofatumumab in the treatment of non-Hodgkin's lymphomas
Lionel Karlin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Biosimilars: The naming puzzle
Rajneesh Kumar Gaur
INDIAN JOURNAL OF PHARMACOLOGY (2015)
Clinical trial development for biosimilars
Rieke Alten et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa
Ombretta Annibali et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity
Mariana P. Miranda-Hernandez et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
Raffaele Iorio et al.
JOURNAL OF NEUROLOGY (2015)
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
O. Middleton et al.
LEUKEMIA (2015)
B lymphocytes in neuromyelitis optica
Jeffrey L. Bennett et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
Guillaume Cartron et al.
BLOOD (2014)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
Perforin: an important player in immune response
Iwona Osinska et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Hyon-Zu Lee et al.
CLINICAL CANCER RESEARCH (2014)
Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Kirit M. Ardeshna et al.
LANCET ONCOLOGY (2014)
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
Andrew Davies et al.
LANCET ONCOLOGY (2014)
Stability of stock and diluted rituximab
Yang Zhang et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2013)
Predictive biomarkers may help individualize treatment for patients with follicular lymphoma
Mary Kay Barton
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
Sarwish Rafiq et al.
JOURNAL OF IMMUNOLOGY (2013)
The INN crowd
[Anonymous]
NATURE BIOTECHNOLOGY (2013)
Analytical characterization of biosimilar antibodies and Fc-fusion proteins
Alain Beck et al.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY (2013)
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
George W. Small et al.
PEERJ (2013)
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
Partha Sarathi Roy et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2013)
Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays
Josee Golay et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
The regulatory framework of biosimilars in the European Union
Paola Minghetti et al.
DRUG DISCOVERY TODAY (2012)
High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism
Yuji Mishima et al.
INTERNATIONAL IMMUNOLOGY (2012)
Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
Xuan Jin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Novel CD20 monoclonal antibodies for lymphoma therapy
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
BCL2 mutations in diffuse large B-cell lymphoma
J. M. Schuetz et al.
LEUKEMIA (2012)
Rituximab for Patients With Refractory Mucous Membrane Pemphigoid
Christelle Le Roux-Villet et al.
ARCHIVES OF DERMATOLOGY (2011)
Clinical programs in the development of similar biotherapeutic products: Rationale and general principles
Alexander Berghout
BIOLOGICALS (2011)
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
William G. Wierda et al.
BLOOD (2011)
The future of anti-CD20 monoclonal antibodies: are we making progress?
Waleed Alduaij et al.
BLOOD (2011)
Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2011)
Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives
Christine Bezombes et al.
MOLECULAR CANCER RESEARCH (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2011)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Chemotherapy-Induced Genotoxic Stress Promotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling Missing-Self Recognition
Jason H. Fine et al.
CANCER RESEARCH (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cell culture processes for monoclonal antibody production
Feng Li et al.
MABS (2010)
Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers
Thomas Doerner et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Rituximab: Therapeutic Benefit! Vitamin R?
Clifton Mo et al.
SEMINARS IN HEMATOLOGY (2010)
Rituximab in Chronic Lymphocytic Leukemia
Samantha M. Jaglowski et al.
SEMINARS IN HEMATOLOGY (2010)
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Nathalie A. Johnson et al.
BLOOD (2009)
Update on therapeutic options in Waldenstrom macroglobulinemia
Xavier Leleu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells
Andrei Ivanov et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Kai Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Structural basis for recognition of CD20 by therapeutic antibody rituximab
Jiamu Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
Marco Ladetto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells
Lars Fischer et al.
EXPERIMENTAL HEMATOLOGY (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
RO Dillman
CLINICAL AND EXPERIMENTAL MEDICINE (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Combining radiotherapy and immunotherapy: A revived partnership
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking
TL Unruh et al.
IMMUNOLOGY (2005)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mouse CD20 expression and function
J Uchida et al.
INTERNATIONAL IMMUNOLOGY (2004)
Store-operated cation entry mediated by CD20 in membrane rafts
HD Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma
M Raderer et al.
ONCOLOGY (2003)
Treatment of Waldenstrom's macroglobulinemia with rituximab
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia
J Perz et al.
LEUKEMIA & LYMPHOMA (2002)
Rituximab dose-escalation trial in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
